The class includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro, a dual GLP-1/GIP receptor agonist), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), and lixisenatide (Adlyxin)
This measured progression has become standard across GLP-1 therapy whether treating weight or diabetes, reflecting clinical experience showing better long-term adherence with slower titration
The BALANCE Model, announced December 2025, creates a Medicare GLP-1 payment demonstration beginning July 2026
As an example, although both carbon nanotubes and GO generated using carbon nanomaterials, it has been previously indicated that GO materials have different toxicity for neurons